A Phase 2B/Phase 3 Study of OT-101 With mFOLFIRINOX in Advanced Pancreatic Cancer

Recruiting Phase 2,Phase 3 NCT06079346

Study Description

A Study of an Experimental Drug (OT-101) Combined With Chemotherapy in Advanced Pancreatic Cancer

Study Details

Registry ID:: NCT06079346
Conditions:: Pancreatic Ductal Adenocarcinoma
Phase:: Phase 2,Phase 3
Target Enrollment:: 455 participants
Start Date:: May 1, 2024
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (2 sites)

Karmanos Cancer Center
Detroit, MichiganUnited States, United States
Baylor College of Medicine
Houston, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →